Senseonics Q4 2025 preliminary revenue $14.2M (+71% YoY); FY2025 $35.2M; guides FY2026 $58-62M

Senseonics Holdings, Inc.

2025-FY EPS reported -$1.66 revenue$35,257,000

Preliminary Q4 2025 revenue $14.2M (+71% YoY); FY2025 revenue $35.2M (+57% YoY); cash $94.3M.
Patient base grew 103% in Q4 2025 vs Q4 2024; largest new patient addition in company history.
Received FDA IDE approval to begin pivotal trial for self-powered Gemini sensor; first patients enrolled.
2026 revenue guidance $58-62M (65-76% growth); gross margin ~50%; commercial transition from Ascensia effective Jan 1, 2026.
First commercial patients using pump partner Sequel's twiist insulin delivery system with Eversense 365 compatibility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.